Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Ukrajna
4 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Cherkasy, Ivano-Frankivsk, Khmelnytskiy, Kyiv, Lviv
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 2/3. fázisTaking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Cherkasy, Ivano-Frankivsk, Kyiv, Lviv
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - 1. fázisTaking peopleDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- Where
- Kyiv
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00 - 1. fázisTaking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- Kyiv
- Életkor
- 18 év and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00